| References: |
FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo.
FG-2216 was orally bioavailable and induced significant and reversible Epo induction in vivo (82- to 309-fold at 60 mg/kg). Chronic oral dosing in male rhesus macaques was well tolerated, significantly increased erythropoiesis, and prevented anemia induced by weekly phlebotomy. Furthermore, modest increases in HbF-containing red cells and reticulocytes were demonstrated by flow cytometry, though significant increases in HbF were not demonstrated by high-pressure liquid chromatography (HPLC). For the detailed information of FG2216, the solubility of FG2216 in water, the solubility of FG2216 in DMSO, the solubility of FG2216 in PBS buffer, the animal experiment (test) of FG2216, the cell expriment (test) of FG2216, the in vivo, in vitro and clinical trial test of FG2216, the EC50, IC50,and affinity,of FG2216, For the detailed information of FG2216, the solubility of FG2216 in water, the solubility of FG2216 in DMSO, the solubility of FG2216 in PBS buffer, the animal experiment (test) of FG2216, the cell expriment (test) of FG2216, the in vivo, in vitro and clinical trial test of FG2216, the EC50, IC50,and affinity,of FG2216, Please contact DC Chemicals. |
